Individuals with SARS-CoV-2 infection can develop symptoms that persist well beyond the
acute phase of COVID-19 or emerge after the acute phase, lasting for weeks or months after …

Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …

Rationale: Shared symptoms and genetic architecture between coronavirus disease (COVID-
19) and lung fibrosis suggest severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Objectives To determine the prevalence of organ impairment in long COVID patients at 6
and 12 months after initial symptoms and to explore links to clinical presentation. Design …

Interstitial lung disease and associated fibrosis occur in a proportion of individuals who have
recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Several millions of individuals are estimated to develop post-acute sequelae SARS-CoV-2
condition (PASC) that persists for months after infection. Here we evaluate the immune …

Fibrosis is the concluding pathological outcome and major cause of morbidity and mortality
in a number of common chronic inflammatory, immune-mediated and metabolic diseases …

Fibrotic interstitial lung diseases (fILDs) have poor survival rates and lack effective therapies.
Despite evidence for immune mechanisms in lung fibrosis, immunotherapies have been …

Background The COVID-19 pandemic follows severe acute respiratory syndrome (SARS)
and Middle East respiratory syndrome (MERS) coronavirus epidemics. Some survivors of …

Introduction Persisting respiratory symptoms in COVID-19 survivors may be related to
development of pulmonary fibrosis. We assessed the proportion of chest CT scans and …